Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Median Technologies's revenue for the
six
months ended in Dec. 2025 was €12.06 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €23.36 Mil.
Median Technologies's Revenue per Share for the
six
months ended in Dec. 2025 was €0.22.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.75.
Warning Sign:
Median Technologies revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Median Technologies was -48.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -24.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -8.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Median Technologies's highest 3-Year average Revenue per Share Growth Rate was 59.80% per year. The lowest was -24.90% per year. And the median was 14.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Median Technologies Revenue Related Terms
Median Technologies Revenue Historical Data
* Premium members only.
The historical data trend for Median Technologies's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Median Technologies's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Median Technologies Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Median Technologies's Revenue distribution charts can be found below:
* The bar in red indicates where Median Technologies's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €23.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Median Technologies (XPAR:ALMDT) has a Revenue of €23.36 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Median Technologies and its competitors.
Is Median Technologies' Revenue too high?
Median Technologies' current Revenue is €23.36 Mil. Overall, Median Technologies has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Median Technologies' Revenue compare to ABT and SYK?
Median Technologies' Revenue of €23.36 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Median Technologies and its competitors. Median Technologies's current Revenue is €23.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Median Technologies stock overvalued right now?
Based on GuruFocus' analysis, Median Technologies (XPAR:ALMDT) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.69, compared to a current price of €4.69 — trading 177.5% above its estimated fair value. The current Revenue is €23.36 Mil. Median Technologies' overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Median Technologies (XPAR:ALMDT), the current Revenue is €23.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Median Technologies (XPAR:ALMDT) Overvalued in 2026?
Based on GuruFocus' analysis, Median Technologies stock appears to be overvalued.
The current stock price of €4.69 is trading 177.5% above its estimated GF Value™ of €1.69.
GuruFocus considers Median Technologies to be Significantly Overvalued.
Key valuation signals for XPAR:ALMDT:
Revenue: €23.36 Mil
GF Value™: €1.69 vs. price of €4.69 (177.5% above fair value)
No single metric tells the full story. See the XPAR:ALMDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The company focuses on the oncology clinical trials market and the cancer patient care market. The company has two platforms, iSee for imaging services in clinical trials and eyonis for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer. Its revenue is generated from contracts for providing imaging services for oncology clinical trials using dedicated software. Geographically, the company generates revenue from EMEA, the USA/Canada, and China.
50GF Score
Get the complete analysis for XPAR:ALMDT
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALMDT has been successfully added to your 
